ARRIVENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ARRIVENT BIOPHARMA, INC. (AVBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 202.36 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 175.01K shares.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 27.35K shares.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 205.10K shares.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was 0.00 shares.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 258.99K shares, a 241.24% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 75.89K shares, a 82.44% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 41.60K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 175.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 202.36K shares 10-Q · filed 2026-08-12 | 407.47K shares derived: sum of 3 quarters · filed 2026-08-12 | |
| 2026-03-31 | 27.35K shares 10-Q · filed 2026-05-11 | 232.45K shares derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2025-12-31 | 205.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 258.99K shares 10-K · filed 2026-03-05 | ||
| 2025-09-30 | 53.88K shares 10-Q · filed 2025-11-10 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 53.66K shares derived: sum of 2 quarters · filed 2025-03-03 | 53.63K shares derived: sum of 3 quarters · filed 2025-03-03 | 75.89K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 53.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 53.63K shares derived: sum of 2 quarters · filed 2024-11-14 | 75.89K shares 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -33.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 22.24K shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 22.27K shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 41.60K shares 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |